Recognition of the nonclassical MHC class I molecule H2-M3 by the receptor Ly49A regulates the licensing and activation of NK cells-Reference-Cited by-同舟云学术

Recognition of the nonclassical MHC class I molecule H2-M3 by the receptor Ly49A regulates the licensing and activation of NK cells

Published:2012-11-11 Issue:12 Volume:13 Page:1171-1177
ISSN:1529-2908
Container-title:Nature Immunology
language:en
Short-container-title:Nat Immunol

Author:

Andrews Daniel M,Sullivan Lucy C,Baschuk Nikola,Chan Christopher J,Berry Richard,Cotterell Claire L,Lin Jie,Halse Heloise,Watt Sally V,Poursine-Laurent Jennifer,Wang Chyung-Ru,Scalzo Anthony A,Yokoyama Wayne M,Rossjohn Jamie,Brooks Andrew G,Smyth Mark J

Publisher

Springer Science and Business Media LLC

Subject

Immunology,Immunology and Allergy

Link

http://www.nature.com/articles/ni.2468.pdf

Reference50 articles.

1. Chan, C.J. et al. Can NK cells be a therapeutic target in human cancer? Eur. J. Immunol. 38, 2964–2968 (2008).

2. Ljunggren, H.G. & Malmberg, K.J. Prospects for the use of NK cells in immunotherapy of human cancer. Nat. Rev. Immunol. 7, 329–339 (2007).

3. Andoniou, C.E. et al. Natural killer cells in viral infection: more than just killers. Immunol. Rev. 214, 239–250 (2006).

4. Karlhofer, F.M. et al. MHC class I alloantigen specificity of Ly-49+ IL-2-activated natural killer cells. Nature 358, 66–70 (1992).

5. Yu, Y.Y. et al. The role of Ly49A and 5E6(Ly49C) molecules in hybrid resistance mediated by murine natural killer cells against normal T cell blasts. Immunity 4, 67–76 (1996).

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Expression of a single inhibitory Ly49 receptor is sufficient to license NK cells for effector functions;2024-06-06

2. Unleashing Natural IL18 Activity Using an Anti-IL18BP Blocker Induces Potent Immune Stimulation and Antitumor Effects;Cancer Immunology Research;2024-04-09

3. Ribosylation of the CD8αβ heterodimer permits binding of the nonclassical major histocompatibility molecule, H2-Q10;Journal of Biological Chemistry;2021-10

4. Immunomodulation: An immune regulatory mechanism in carcinoma therapeutics;International Immunopharmacology;2021-10

5. Innate Lymphocyte Mechanisms in Skin Diseases;Annual Review of Immunology;2020-04-26